Genomic Characterization of Lymphomas in Patients with Inborn Errors of Immunity
Xiaofei Ye,Paul J. Maglione,Claudia Wehr,Xiaobo Li,Yating Wang,Hassan Abolhassani,Elena Deripapa,Dongbing Liu,Stephan Borte,Likun Du,Hui Wan,Andreas Ploetner,Yvonne Giannoula,Huai-Bin Ko,Yong Hou,Shida Zhu,Jennifer K. Grossman,Birgitta Sander,Bodo Grimbacher,Lennart Hammarstrom,Alina Fedorova,Sergio D. Rosenzweig,Anna Shcherbina,Kui Wu,Klaus Warnatz,Charlotte Cunningham-Rundles,Qiang Pan-Hammarstrom
DOI: https://doi.org/10.1182/bloodadvances.2021006654
IF: 7.642
2022-01-01
Blood Advances
Abstract:Patients with inborn errors of immunity (IEI) have a higher risk of developing cancer, especially lymphoma. However, the molecular basis for IEI-related lymphoma is complex and remains elusive. Here, we perform an in-depth analysis of lymphoma genomes derived from 23 IEI patients. We identified and validated disease-causing or -associated germline mutations in 14 of 23 patients involving ATM, BACH2, BLM, CD70, G6PD, NBN, PIK3CD, PTEN, and TNFRSF13B. Furthermore, we profiled somatic mutations in the lymphoma genome and identified 8 genes that were mutated at a significantly higher level in IEI-associated diffuse large B-cell lymphomas (DLBCLs) than in non-IEI DLBCLs, such as BRCA2, NCOR1, KLF2, FAS, CCND3, and BRWD3. The latter, BRWD3, is furthermore preferentially mutated in tumors of a subgroup of activated phosphoinositide 3-kinase δ syndrome patients. We also identified 5 genomic mutational signatures, including 2 DNA repair deficiency-related signatures, in IEI-associated lymphomas and a strikingly high number of inter- and intrachromosomal structural variants in the tumor genome of a Bloom syndrome patient. In summary, our comprehensive genomic characterization of lymphomas derived from patients with rare genetic disorders expands our understanding of lymphomagenesis and provides new insights for targeted therapy.